HMGN1P17

Across TCGA pan-cancer cohorts, HMGN1P17 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated HMGN1P17 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher HMGN1P17 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated HMGN1P17 expression acts as an unfavorable survival marker, although some lineages such as LUSC and MESO show a favorable association.

LIHC, UCS, and UCEC are the cancer types where HMGN1P17 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	All	0.418	0.577	<.001	109	view →
UCS	OS	Tertile	All	0.358	0.729	<.001	98	view →
UCEC	OS	Median	II,III,IV	0.279	0.714	<.001	88	view →
TGCT	DFS	Tertile	III,IV	0.340	1.000	.002	60	view →
COAD	OS	Tertile	All	0.374	0.722	<.001	48	view →
LUSC	DFS	Tertile	II,III,IV	0.613	0.339	.001	42	view →
LUAD	DFS	Tertile	All	0.504	0.709	.001	39	view →
KICH	DFS	Tertile	III,IV	0.065	1.000	<.001	35	view →
LGG	OS	Tertile	All	0.652	0.867	<.001	33	view →
MESO	OS	Median	III,IV	0.789	0.295	.002	27	view →
HNSC	OS	Tertile	II,III,IV	0.632	0.335	.016	27	view →
BLCA	DFS	Tertile	All	0.262	0.357	.041	21	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

HMGN1P17–LIHC (DFS)

Open the LIHC breakdown →